CD274 and neoplasm: ICIs—including Pembrolizumab, Nivolumab, Atezolizumab, and Durvalumab—achieve anti-tumor effects by enhancing T-cell activity through PD-1/PD-L1 pathway inhibition (Zhong et al., 2020; Tekiki et al., 2021; Schomberg, 2019).